Reason: Registry status: TERMINATED, WITHDRAWN
Stage at discontinuation: phase_3
Explore licensed vaccines, adverse event reporting data, and history for this disease.
Multi-Jurisdiction Regulatory Status
Official licensing, rolling submissions, or authorization status tracked across major health authorities.
| Regulatory Authority | Status & Details |
|---|---|
| US FDA | Not Filed / Pre-submission |
| EMA (Europe) | Not Filed / Pre-submission |
| Health Canada | Not Filed / Pre-submission |
| TGA (Australia) | Not Filed / Pre-submission |
Scientific Profile & Documentation
- Platform Architecture
- mRNA
- Lead Developer
- CureVac
- Next Expected Milestone
- Primary completion (most advanced trial): 2022-01 (registry estimate)
- Analyst & Development Notes
- Auto-grouped from 2 ClinicalTrials.gov record(s) sharing intervention/sponsor. Phases and timelines are registry fields and may lag company disclosures.
- Primary Source Documentation
- ClinicalTrials.gov NCT04838847 →
- Additional Sources & Literature
- NCT04860258 on ClinicalTrials.gov (2026-07-10)
Registered Clinical Trials & Studies
Direct registry links to active, completed, or pivotal registration studies across phases.
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Yo
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults
Milestone Overview
-
Stage VerificationDiscontinued / Inactive confirmed as of 2026-07-10.
-
Target MilestonePrimary completion (most advanced trial): 2022-01 (registry estimate)
Vaccine Data Navigator Candidate Profile Registry:
This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.